February 2018, Vol 8, No 2

A Dynamic FDA Has Led to More Rapid Cancer Drug Development

By Wayne Kuznar

Cancer Drugs R&D

New Breast Cancer Treatment Strategies Highlighted at SABCS 2017

By Phoebe Starr

Breast Cancer, SABCS 2017

The Butterfly Effect: Improving the Chemotherapy Visit Experience

By Gail Thompson

Practice Operations

Authority Over Medical Practices—Something to Watch

By Dawn Holcombe, MBA, FACMPE, ACHE

From the Editor

CDK4/CDK6 Inhibitors Effective in Older Women, but Have More Side Effects

By Phoebe Starr

Breast Cancer, SABCS 2017

Switching on the Light: A Model Immunotherapy Program for Oncology Practices

By Gail Thompson

Combining Immunotherapy and Radiotherapy Shows Good Synergy

Silent Patients Find Their Voices Through an Advocate’s Journey

By Meg Barbor, MPH

Patients Perspectives

Managing Adverse Events Linked to Immune Checkpoint Inhibitors: What Is Your Knowledge Level?

By Eileen Koutnik-Fotopoulos

Side-Effects Management

The Challenges of Oral Cancer Drugs Use and Side-Effects Management

By Meg Barbor, MPH

Side-Effects Management

There is only one “king of the road” when it comes to dealing with the adverse side effects of oral cancer drugs, and that is not the healthcare professional, according to Christine B. Boers-Doets, MSc, of the Netherlands Leiden University Medical Center, author of The TARGET System, and creator of the 7 Pillars of Ultimate Drug Success formula. Read More ›

Page 1 of 2

1
2